Therapy corrects common GAA splicing defect in lab studies
A therapeutic approach designed to correct the cellular defect caused by a common mutation in people with late-onset Pompe disease (LOPD) worked as intended to increase activity of the acid alpha glucosidase (GAA) enzyme in lab studies, according to a study. People with Pompe disease are lacking in…